74 related articles for article (PubMed ID: 17826527)
1. Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.
Zhang Z; Stanfield J; Frenkel E; Kabbani W; Hsieh JT
Urology; 2007 Aug; 70(2):396-401. PubMed ID: 17826527
[TBL] [Abstract][Full Text] [Related]
2. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Kanzaki M; Kakinuma H; Kumazawa T; Inoue T; Saito M; Narita S; Yuasa T; Tsuchiya N; Habuchi T
Oncol Rep; 2007 Apr; 17(4):761-7. PubMed ID: 17342312
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
Yoo J; Park SS; Lee YJ
J Cell Biochem; 2008 Aug; 104(5):1636-46. PubMed ID: 18404675
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Nishida K; Komiyama T; Miyazawa S; Shen ZN; Furumatsu T; Doi H; Yoshida A; Yamana J; Yamamura M; Ninomiya Y; Inoue H; Asahara H
Arthritis Rheum; 2004 Oct; 50(10):3365-76. PubMed ID: 15476220
[TBL] [Abstract][Full Text] [Related]
6. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
Burich RA; Holland WS; Vinall RL; Tepper C; White RW; Mack PC
BJU Int; 2008 Nov; 102(10):1458-66. PubMed ID: 18565171
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
9. Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis.
Reiner T; de las Pozas A; Gomez LA; Perez-Stable C
Cancer Lett; 2009 Apr; 276(1):21-31. PubMed ID: 19046802
[TBL] [Abstract][Full Text] [Related]
10. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
[TBL] [Abstract][Full Text] [Related]
11. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.
Karam JA; Fan J; Stanfield J; Richer E; Benaim EA; Frenkel E; Antich P; Sagalowsky AI; Mason RP; Hsieh JT
Int J Cancer; 2007 Apr; 120(8):1795-802. PubMed ID: 17230511
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Adachi M; Zhang Y; Zhao X; Minami T; Kawamura R; Hinoda Y; Imai K
Clin Cancer Res; 2004 Jun; 10(11):3853-62. PubMed ID: 15173094
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
[TBL] [Abstract][Full Text] [Related]
15. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
17. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
[TBL] [Abstract][Full Text] [Related]
18. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
Kawano T; Horiguchi-Yamada J; Iwase S; Akiyama M; Furukawa Y; Kan Y; Yamada H
Anticancer Res; 2004; 24(5A):2705-12. PubMed ID: 15517875
[TBL] [Abstract][Full Text] [Related]
19. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
Musende AG; Eberding A; Jia W; Ramsay E; Bally MB; Guns ET
Prostate; 2010 Sep; 70(13):1437-47. PubMed ID: 20687217
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
